Finance

Lists
CMXHF:OTCMKTS
CSL Ltd
$120.00
0.00%
(0.00) 1D
Aug 20, 1:34:18 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMXHF...
Mkt. cap
82.53B
Avg. vol.
1.42K
Volume
90.00
52-wk high
$148.36
52-wk low
$63.84
Beta
0.55
Shares outstanding
478.91M
No. of employees
33K
Mkt. cap
82.53B
Avg. vol.
1.42K
Volume
90.00
52-wk high
$148.36
52-wk low
$63.84
Beta
0.55
Shares outstanding
478.91M
No. of employees
33K
News stories
From web sources and news partners
Profile
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
About CSL Ltd
CEOPaul McKenzie
Employees32.7K
Founded1916
HeadquartersMelbourne, Victoria, Australia
SectorBiotechnology
Websitecsl.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.17B
4.17B
-
3.73B
Cost of goods sold
1.94B
1.94B
-
-
Cost of revenue
1.94B
1.94B
-
-
Research and development expenses
300.00M
300.00M
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
612.50M
612.50M
-
693.00M
Operating expense
912.50M
912.50M
1.00B
-
Total operating expenses
2.85B
2.85B
-
2.93B
Operating income
1.32B
1.32B
802.00M
-
Other non operating income
-
-
-
-
EBT including unusual items
190.00M
190.00M
-
-
EBT excluding unusual items
1.22B
1.22B
699.50M
-
Income tax expense
47.00M
47.00M
-
-597.50M
Effective tax rate
24.74%
24.74%
26.75%
26.75%
Other operating expenses
-
-
-
-
Net income
200.50M
200.50M
-
-
Net profit margin
4.81%
4.81%
-
-
Earnings per share
-
-
-
-
Interest and investment income
9.00M
9.00M
-
6.00M
Interest expense
-106.50M
-106.50M
-
-108.50M
Net interest expenses
-97.50M
-97.50M
-
-102.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.56B
1.56B
974.00M
-
Gain or loss from assets sale
22.50M
22.50M
500.00K
500.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps